Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08046032 + sasanlimab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (PF-08046032), Subcutaneous (sasanlimab)
01
Overview
PF-08046032 + sasanlimab is a combination of two investigational biologic drugs developed by Pfizer, being studied for their anti-tumor effects in advanced lymphomas and solid tumors. PF-08046032 is an antibody-drug conjugate (ADC) targeting CD25 (IL-2 receptor alpha) present on certain cell populations, including regulatory T cells (Tregs), aiming to selectively deplete these and promote anti-tumor immune response[2][4][7]. Sasanlimab is a monoclonal antibody that inhibits programmed cell death protein 1 (PD-1), thus serving as an immune checkpoint inhibitor to augment T cell-mediated anti-tumor activity[1][7]. The combination is being evaluated in adult patients with relapsed/refractory lymphoma and advanced/metastatic solid tumors. Both drugs are still investigational and not currently FDA approved for any indication[4][7].
- Brand names
- PF-08046032 (no brand name)sasanlimab (no brand name)
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PF-08046032 + sasanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08046032 + sasanlimab.